InTandem Capital Partners Backs Clinilabs

InTandem Capital Partners has partnered with the founder and management team at Clinilabs, a global, full-service contract research organization (CRO) that provides a range of central nervous system (CNS) drug and device development services to the pharmaceutical, biotechnology, and medical technology industries.

Since the company’s 2000 inception, Clinilabs has established itself as a market leader in neuroscience therapeutics, focusing efforts exclusively in neurology, psychiatry, addiction, and rare CNS disorders. “I am pleased to announce that Clinilabs has partnered with InTandem to pursue the next stages of our growth,” Clinilabs President/CEO Gary Zammit, Ph.D., said. “Clinilabs’ decision to partner came down to the people at InTandem. InTandem shares our vision for the company, has deep expertise in the sector, and provides value-added operating resources that we sought to build our company.”

Clinilabs has conducted more than 750 CNS clinical trials since 2000 and has played a pivotal role in the approval of 22 new therapies across 13 CNS indications. The company has successfully participated in routine audits by the U.S. Food and Drug Administration, European Medicines Agency, Pharmaceuticals and Medical Devices Agency, and Saudi Food and Drug Agency.

“As the market for CNS therapeutics continues to grow, it is essential for sponsors to work with a CRO that understands the unique challenges that come with neuroscience clinical trials. InTandem recognizes Clinilabs’ deep expertise, and we are thrilled to collaborate with Gary and his team,” InTandem Partner Mehran Ahmed stated. “We look forward to supporting the company in delivering high-quality, timely, and cost-effective drug and device development services that will accelerate the availability of new CNS therapeutics to the patients who need them most.”

Clinilabs’ solutions extend from first-in-human through the end of Phase 3, and include services such as trial management, feasibility and site selection, risk-based monitoring, data management, core laboratories, biostatistics, medical writing, and trial execution at its wholly-owned units and at independent investigator sites worldwide.

“This is an especially exciting time for our organization’s future. Our team remains focused on the ultimate measure of our success—improving the lives of patients who are fighting battles against central nervous system disorders,” Clinilabs Chief Operating Officer Eileen McAuley commented.

InTandem Capital Partners is a private equity firm that invests in and helps accelerate the growth of select healthcare services companies. Its goal is to build businesses of significant value by working collaboratively with its management team partners. InTandem is solely focused on investing in businesses that align closely with the Healthcare Quintuple Aim—the simultaneous pursuit of enhanced patient experience, elevated provider experience, improved clinical outcomes, greater healthcare equity, and lower care cost delivery. The firm is comprised of former business executives and experienced investors who provide strategic, acquisition, and operating expertise to help companies significantly increase their value and their contribution to an improved healthcare system. InTandem provides active support to the management of its portfolio companies directly and leverages its network of industry executives to augment its capabilities.

Clinilabs is a global, full-service contract research organization focused exclusively on CNS drug, device, and technology development. With deep expertise in CNS, Clinilabs is committed to developing therapies that address a range of psychiatric, neurological, and substance use disorders, as well as rare and ultra-rare CNS diseases. Clinilabs partners with pharmaceutical, biotechnology, and medical device companies to provide clinical drug development services from first-in-human to Phase 3 trials, aimed at accelerating the availability of new CNS therapies in the market.